Dolutegravir

규격

1051375-16-6CAS 번호

809-888-1EC 번호

(3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-13-carboxamideIUPAC 명칭

C20H19F2N3O5화학식

419.4 g/mol분자량

Dolutegravir; 1051375-16-6; GSK1349572; S/GSK1349572; GSK 1349572; GSK-1349572; S-349572; (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide; DKO1W9H7M1; CHEBI:76010; DTXSID90909356; 2H-Pyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazine-9-carboxamide, N-((2,4-difluorophenyl)methyl)-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS)-; dolutegravirum; (4R,12aS)-N-((2,4-difluorophenyl)methyl)-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-Pyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazine-9-carboxamide; (4R,12aS)-N-((2,4-difluorophenyl)methyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,12,12a-tetrahydro-2H-pyrido(5,6)pyrazino(2,6-b)(1,3)oxazine-9-carboxamide; (4R,12aS)-N-[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,12,12a-tetrahydro-2H-pyrido[5,6]pyrazino[2,6-b][1,3]oxazine-9-carboxamide; RefChem:56964; J05AX12; DTXCID701338419; (14C)-(4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-(1,3)oxazino(3,2-a)pyrido(1,2-d)pyrazine-9-carboxamide; (4R,9aS)-5-hydroxy-4-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diaza-anthracene-7-carboxylic acid-2,4 difluorobenzylamide; 2H-Pyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazine-9-carboxamide, N-((2,4-difluorophenyl)methyl)-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS); Tivicay; Dolutegravir (GSK1349572); (4r,12as)-N-(2,4-Difluorobenzyl)-7-Hydroxy-4-Methyl-6,8-Dioxo-3,4,6,8,12,12a-Hexahydro-2h-Pyrido[1',2':4,5]pyrazino[2,1-B][1,3]oxazine-9-Carboxamide; Dolutegravir DTG; Dolutegravir [USAN]; (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-13-carboxamide; Dolutegravir (USAN); GSK1349572A; Tivicay (TN); Dolutegravir (0.1 mg/mL in Methanol); Dolutegravir [USAN:INN]; UNII-DKO1W9H7M1; Soltegravir; Dolutegravir?; HSDB 8152; C20H19F2N3O5; MFCD20488027; S-GSK1349572; 1051375-16-6 (free); 3s3m; 3s3n; 3s3o; Dolutegravir (Standard); (4R,12aS)-N-[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,12,12a-tetrahydro-2H-pyrido[[?]:[?]]pyrazino[[?]][1,3]oxazine-9-carboxamide; DOLUTEGRAVIR [MI]; DOLUTEGRAVIR [INN]; DOLUTEGRAVIR [VANDF]; SCHEMBL82071; MLS006011137; DOLUTEGRAVIR [WHO-DD]; GTPL7365; orb1300988; orb3141325; CHEMBL1229211; SCHEMBL15397915; SCHEMBL29357473; RHWKPHLQXYSBKR-BMIGLBTASA-N; GLXC-90267; EX-A1695; BDBM50062551; EBC-27030; HY-13238R; s2667; AKOS025396657; S/GSK-1349572; CCG-268876; CS-0454; DB08930; FD43372; NCGC00346629-01; NCGC00346629-02; NCGC00346629-06; NCGC00346629-11; (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.0^{3,8}]tetradeca-10,13-diene-13-carboxamide; AC-28371; AS-75277; HY-13238; SMR004702915; NS00099377; T6198; S/GSK1349572,GSK1349572; D10066; EN300-7409916; F799806; Q937224; Z2235801952; (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.0(3),?]tetradeca-10,13-diene-13-carboxamide; (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.0,3,8]tetradeca-10,13-diene-13-carboxamide; (4R,12.ALPHA.S)-N-((2,4-DIFLUOROPHENYL)METHYL)-7-HYDROXY-4-METHYL-6,8-DIOXO-3,4,6,8,12,12.ALPHA.-HEXAHYDRO-2H-PYRIDO(1',2':4,5)PYRAZINO(2,1-.BETA.)(1,3)OXAZINE-9-CARBOXAMIDE; (4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-[1,3]oxazino[3,2-a]pyrido[1,2-d]pyrazine-9-carboxamide; (4R,12aS)-N-(2,4-Difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-[1,3]oxazino[3,2-d]pyrido[1,2-a]pyrazine-9-carboxamide; (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide동의어